Τίτλος:
Immunostimulation and Coagulopathy in COVID-19 Compared to Patients With H1N1 Pneumonia or Bacterial Sepsis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
BACKGROUND/AIM: Multiple reports from all over the world link COVID-19 with endothelial/coagulation disorders as well as a dysregulated immune response. This study tested the hypothesis that immunostimulation will be greater in COVID-19 patients than in patients with H1N1 infection or bacterial sepsis. Also, whether an increase in immune stimulation will be accompanied by a more severely affected endothelium/coagulation system was examined. PATIENTS AND METHODS: Twenty-three septic patients, admitted in the Intensive Care Unit (ICU), were enrolled (9 with SARS-CoV-2, 5 with H1N1 pneumonia, 9 with bacterial sepsis). Myeloperoxidase (MPO) activity along with certain endothelial/coagulation factors were assessed on admission (time point 1) and at either improvement or deterioration (time point 2). RESULTS: MPO levels were significantly higher in COVID-19 patients compared to both other groups. Furthermore, in patients with COVID-19, vWF levels did not differ significantly, fVIII levels were lower while ADAMTS-13 activity was higher compared to patients with H1N1 pneumonia and bacterial sepsis (a trend in the latter). CONCLUSION: Increased immunostimulation was noted in COVID-19 patients compared to other septic patients; however, this was not accompanied by greater disturbance of the clotting system and/or more severe endothelial injury. Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Συγγραφείς:
Papadakis, D.-D.
Politou, M.
Kompoti, M.
Vagionas, D.
Kostakou, E.
Theodoulou, D.
Kaniaris, E.
Rovina, N.
Panayiotakopoulos, G.
Dimopoulos, S.
Koutsoukou, A.
Vasileiadis, I.
Περιοδικό:
In vivo (Athens, Greece)
Λέξεις-κλειδιά:
blood clotting disorder; complication; human; immunization; Influenza A virus (H1N1); sepsis, Blood Coagulation Disorders; COVID-19; Humans; Immunization; Influenza A Virus, H1N1 Subtype; SARS-CoV-2; Sepsis
DOI:
10.21873/invivo.12786
